Metropolitan AntiViral Drug Accelerator: Administrative Core
Official title: Metropolitan AntiViral Drug Accelerator (Admin Core)
Funded at Hackensack University Medical Center · NIH-11617027 · Data updated 2026-11-12
A centralized management hub is being built to help move promising antiviral drugs for COVID-19 and similar viruses from discovery toward potential products.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | May 16, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $706,746 |
| NIH project number | 4U19AI171401-02 |
| Project ID | NIH-11617027 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include people with COVID-19 or related viral infections who could benefit from future antiviral products developed through MAVDA.
✕Less likely to help
Patients would not directly participate in this administrative core work, but may benefit indirectly if products advance.
What this research studies
This grant funds an Administrative Core to coordinate a collaborative network of program directors, a business director, leadership teams, and expert advisors. It supports streamlined decision-making, resource allocation, and regular scientific exchanges to advance antiviral compounds. The structure includes secure communications, annual reviews, and reporting to NIH to keep projects aligned with urgent public health goals.
Why it matters
Potential benefit: If successful, it could accelerate the development and deployment of antiviral medicines for COVID-19 and other pandemics.
How similar studies have gone: Similar translational consortia have accelerated antiviral development by linking discovery with decision-making and resources.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Perlin, David S — Hackensack University Medical Center
- Study coordinator: Perlin, David S
Related research
Other NIH-funded projects on the same topics.
-
Orally accessible antiviral leaders to fight COVID-19 and related coronaviruses
A research effort to fast-track safe, easy-to-take oral drugs that can treat COVID-19 and other coronaviruses by repurposing and optimizing existing antiviral compounds.
-
Metropolitan Antiviral Drug Accelerator Virology Core
A core team across top hospitals and universities is testing antiviral compounds against SARS-CoV-2 and related coronaviruses to identify promising drugs for COVID-19.
-
Broad-spectrum SARS-CoV-2 protease inhibitor for antiviral therapy
Researchers are developing a new small-molecule drug that blocks a key SARS-CoV-2 enzyme, with potential to treat COVID-19 across multiple virus variants.
-
Metropolitan AntiViral Drug Accelerator: Animal Models
A large NIH-funded effort uses animal models to test new antiviral compounds against SARS-CoV-2 and related viruses to move promising leads toward early development.
-
Metropolis AntiViral Drug Accelerator: Pharmacology Core
A dedicated program to speed up promising antiviral drugs by testing their behavior in the body and choosing the best candidates for further development.
-
Metropolitan Antiviral Drug Accelerator
A national program at Hackensack University Medical Center to help develop and optimize small-molecule drugs that may block key SARS-CoV-2 proteins, potentially slowing COVID-19 replication.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.